On June 17, 2025, Celltrio, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell and gene therapy, announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Wilson Sonsini Goodrich & Rosati advised Celltrio on the transaction.

The new funding will accelerate the global commercialization of RoboCell®, Celltrio’s flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities; expand commercial operations across North America, Europe, and Asia; and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories.

The Wilson Sonsini team that advised Celltrio on the transaction included:

Corporate
Ben Capps
Dani Glazer Signaigo
James Keegan

Regulatory
Nimit Dhir
Jahna Hartwig

For more information, please see Celltrio’s news release.